Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma

Glioblastoma is the most common primary brain malignancy and carries with it a poor prognosis. New agents are urgently needed, however nearly all Phase III trials of GBM patients of the past 25 years have failed to demonstrate improvement in outcomes. In 2019, the National Cancer Institute Clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Degorre, Charlotte, Tofilon, Philip, Camphausen, Kevin, Mathen, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480070/
https://www.ncbi.nlm.nih.gov/pubmed/34583727
http://dx.doi.org/10.1186/s13014-021-01918-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480070/
https://www.ncbi.nlm.nih.gov/pubmed/34583727
http://dx.doi.org/10.1186/s13014-021-01918-y

Ejemplares similares